Higher baseline LDL-C levels amplify the short-term benefit of early intensive statin treatment in acute coronary syndrome

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 1, 2011, Pages 42-48

  Dohi, Tomotaka ^a   Miyauchi, Katsumi ^a   Okazaki, Shinya ^a   Yokoyama, Takayuki ^a   Yanagisawa, Naotake ^a   Tamura, Hiroshi ^a   Kojima, Takahiko ^a   Yokoyama, Ken ^a   Kurata, Takeshi ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute coronary syndrome; Atorvastatin; Short term outcomes

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ADULT; ADVERSE OUTCOME; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME;

EID: 79551668194     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.5587     Document Type: Article

References (22)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278
2. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW: 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with st-elevation myocardial infarction: A report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol, 2008; 51: 210-247
3. Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, Foody JM, Ho PM, Kosiborod MN, Masoudi FA, Nallamothu BK: ACC/AHA 2008 performance measures for adults with st-elevation and non-st-elevation myocardial infarction: A report of the american college of cardiology/american heart association task force on performance measures (writing committee to develop performance measures for st-elevation and non-st-elevation myocardial infarction) developed in collaboration with the american academy of family physicians and american college of emergency physicians endorsed by the american association of cardiovascular and pulmonary rehabilitation, society for cardiovascular angiography and interventions, and society of hospital medicine. J Am Coll Cardiol, 2008; 52: 2046-2099
4. Morrissey RP, Diamond GA, Kaul S: Statins in acute coronary syndromes: Do the guideline recommendations match the evidence? J Am Coll Cardiol, 2009; 54: 1425-1433
5. Hulten E, Jackson JL, Douglas K, George S, Villines TC: The effect of early, intensive statin therapy on acute coronary syndrome: A meta-analysis of randomized controlled trials. Arch Intern Med, 2006; 166: 1814-1821
6. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, Kayikcioglu M, Arntz HR, den Hartog FR, Veeger NJ, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ: Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: A meta-analysis of randomized controlled trials. Jama, 2006; 295: 2046-2056
7. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H: Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH study. Circulation, 2004; 110: 1061-1068
8. Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Yanagisawa N, Tamura H, Kojima T, Yokoyama K, Kurata T, Daida H: Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): A follow- up study. Atherosclerosis, 2010; 210: 497-502
9. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 2002; 360: 7-22
10. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG: Pravastatin in elderly individuals at risk of vascular disease (prosper): A randomised controlled trial. Lancet, 2002; 360: 1623-1630
11. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial--lipid lowering arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet, 2003; 361: 1149-1158
12. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350: 1495-1504
13. Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). JAMA, 2001; 285: 2486-2497
14. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435
15. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA, 2001; 285: 1711-1718
16. Sposito AC, Chapman MJ: Statin therapy in acute coronary syndromes: Mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol, 2002; 22: 1524-1534
17. Law MR, Wald NJ, Thompson SG: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ, 1994; 308: 367-372
18. Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and metaanalysis. BMJ, 2003; 326: 1423
19. Shepherd J: Resource management in prevention of coronary heart disease: Optimising prescription of lipid-lowering drugs. Lancet, 2002; 359: 2271-2273
20. Davidson MH, Robinson JG: Safety of aggressive lipid management. J Am Coll Cardiol, 2007; 49: 1753-1762
21. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): Multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685-696
22. Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E: Baseline lowdensity lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: A PROVE IT-TIMI 22 (pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22) analysis. J Am Coll Cardiol, 2008; 52: 914-920